BAINBRIDGE ISLAND, Wash.--(BUSINESS WIRE)--Emerald BioStructures, a leading provider of integrated structural biology services, today announced the creation its Scientific Advisory Board (SAB). The SAB will collaborate with Emerald BioStructures on the development of its high-throughput gene-to-structure platform for fragment-based drug lead discovery. Board members include Drs. John Hunt, John McCall, John Mulligan, and Lynn Silver. The board will provide independent expertise to support the Company’s fragment-based drug discovery, protein crystallography, structural proteomics, gene engineering, biochemistry, infectious disease, and other scientific matters.
